- Trials with a EudraCT protocol (1,385)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (75)
1,385 result(s) found for: Calcium.
Displaying page 1 of 70.
EudraCT Number: 2013-002188-24 | Sponsor Protocol Number: 2013-002188-24 | Start Date*: 2014-01-16 | |||||||||||||||||||||
Sponsor Name: | |||||||||||||||||||||||
Full Title: REDUCTION OF POST-THYROIDECTOMY TRANSIENT HYPOCALCEMIA WITH CHOLECALCIFEROL 200,000 IU OS ADMINISTERED FOR ONE MONTH BEFORE SURGERY | |||||||||||||||||||||||
Medical condition: Background: 30% of patients undergoing surgery for total thyroidectomy in the first 24 hours may experience a transient hypocalcaemia (serum calcium <8 mg / dl). According to recent studies, pre-s... | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-002280-14 | Sponsor Protocol Number: L00006 CP 403 3A | Start Date*: 2008-07-18 | |||||||||||
Sponsor Name:Pierre Fabre Médicament | |||||||||||||
Full Title: Comparative study of the effect of 4-week treatment with ossein-hydroxyapatite compound versus calcium carbonate on bone biomarkers in young women with low calcium intake. Prospective, monocenter, ... | |||||||||||||
Medical condition: The Active substance of Osteopor is Ossein Hydroxyapatite. Treatment of processes characterized by decalcification: osteoporosis, Cushing syndrome, thyrotoxicosis. | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-001726-14 | Sponsor Protocol Number: 1/2011 | Start Date*: 2011-12-15 | ||||||||||||||||
Sponsor Name:AUSL DI MODENA | ||||||||||||||||||
Full Title: Supplementetion with vitamin D in patients with chronic heart failure and hypovitaminosis D | ||||||||||||||||||
Medical condition: CHRONIC HEART FAILURE (NYHA CLASS II-III) VITAMIN D DEFICIT | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: IT (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-000308-82 | Sponsor Protocol Number: oxalate01 | Start Date*: 2017-02-08 |
Sponsor Name:Universitair Ziekenhuis Brussel | ||
Full Title: Lanthanum Carbonate (Fosrenol®) to reduce oxalate excretion in patients with secondary hyperoxaluria and nephrolithiasis: a short-term, prospective, open-label, efficacy and safety clinical trial | ||
Medical condition: Urolithiasis and secondary hyperoxaluria | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2013-001267-23 | Sponsor Protocol Number: PAT13300CCD | Start Date*: 2013-06-19 | ||||||||||||||||
Sponsor Name:Pharma Patent Kft | ||||||||||||||||||
Full Title: Open label multicentric study to evalute the safety and efficacy of CitrokalciumD 300 mg/300 NE tablets in patients assessed deficiency for supplementation of calcium and vitamin D. | ||||||||||||||||||
Medical condition: Vitamin D and calcium deficiency | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Female | |||||||||||||||||
Trial protocol: HU (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-004176-22 | Sponsor Protocol Number: IMPURE-Study | Start Date*: 2017-04-28 |
Sponsor Name:Medizinische Universität Graz | ||
Full Title: IMProving Ultrafiltration and REmoval of uremic toxins by adapted automated peritoneal dialysis in a single center study (IMPURE-Study). | ||
Medical condition: Chronic kidney disease G5D | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Completed) | ||
Trial results: View results |
EudraCT Number: 2011-002863-84 | Sponsor Protocol Number: | Start Date*: 2012-03-02 |
Sponsor Name:Medizinische Universitaet Wien, AKH Wien, Innere Medizin III, klin.Abteilung fuer Nephrologie und Dialyse | ||
Full Title: Calcitonin stimulation: pentagastrin vs. calcium gluconate - potency, feasibility and tolerance in chronic kidney disease. | ||
Medical condition: investigation of the presence/absence of C-cell abnormalities of the thyroid in chronic kidney disease. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Completed) | ||
Trial results: View results |
EudraCT Number: 2004-001155-11 | Sponsor Protocol Number: OSI-904-202 | Start Date*: 2005-02-25 | |||||||||||
Sponsor Name:OSI Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Randomized, Open Label, Phase II Study of OSI-7904L versus 5-FU/LV as First-Line Treatment in Patients with Unresectable, Locally Advanced or Metastatic Adenocarcinoma of the Biliary Tract | |||||||||||||
Medical condition: Unresectable, locally advanced or metastatic adenocarcinoma of the biliary tract | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-000500-29 | Sponsor Protocol Number: P150911 | Start Date*: 2016-06-03 | |||||||||||
Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP) | |||||||||||||
Full Title: A randomized Crossover TrIal to Compare recombinant human rhPTH(1-34) to the ASsociation alfacalcidol/hydrochlorothiazide in the treatment of Autosomal Dominant Hypocalcemia | |||||||||||||
Medical condition: Autosomal dominant hypocalcemia (ADH) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-000706-30 | Sponsor Protocol Number: A2581175 | Start Date*: 2012-02-09 |
Sponsor Name:Pfizer Inc | ||
Full Title: An Open Label, Randomized, Single Dose, Two-Way Crossover bioequivalence Study Comparing a New 80 mg (2x40 mg) Pediatric Appropriate Formulation to an 80 mg Commercial Atorvastatin Calcium Tablet F... | ||
Medical condition: pharmacokinetic trial | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2012-000728-17 | Sponsor Protocol Number: A2581174 | Start Date*: 2012-02-13 |
Sponsor Name:Pfizer Inc | ||
Full Title: An Open Label, Randomized, Single Dose, Two-Way Crossover Bioequivalence Study Comparing a Pediatric Appropriate Formulation to a 10 mg Commercial Atorvastatin Calcium Tablet Formulation in Healthy... | ||
Medical condition: pharmacokinetic | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2019-002730-36 | Sponsor Protocol Number: CaEP68962 | Start Date*: 2019-11-14 | ||||||||||||||||
Sponsor Name:Department of Dermatology, Bispebjerg Hospital | ||||||||||||||||||
Full Title: Calcium electroporation for basal cell carcinomas – a ’Proof of concept’ study | ||||||||||||||||||
Medical condition: Basal cell carcinomas | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DK (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2007-000573-29 | Sponsor Protocol Number: 20062007 | Start Date*: 2009-10-16 | |||||||||||
Sponsor Name:Amgen Inc | |||||||||||||
Full Title: A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Using Cinacalcet to Correct Hypercalcemia in Renal Transplant Recipients With Autonomous Hyperparathyroid... | |||||||||||||
Medical condition: Renal transplant recipients with hypercalcemia and autonomous hyperparathyroidism | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Prematurely Ended) FR (Completed) ES (Completed) IT (Completed) AT (Completed) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-003387-46 | Sponsor Protocol Number: COCA2 | Start Date*: 2019-10-28 | |||||||||||
Sponsor Name:Research Center for Emergency Medicine Department of Clinical Medicine Aarhus University | |||||||||||||
Full Title: Calcium for Out-of-Hospital Cardiac Arrest – A Randomized, Double-Blind, Placebo-Controlled trial | |||||||||||||
Medical condition: The study will include patients with out-of-hospital cardiac arrest (OHCA). The study will test whether treatment with Calcium Chloride added to standard care will improve survival following OHCA. ... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-002648-10 | Sponsor Protocol Number: ADDI-D | Start Date*: 2014-03-04 |
Sponsor Name:Bruno Farmaceutici S.p.a. | ||
Full Title: THE EFFECT OF A DAILY AND WEEKLY ADMINISTRATION OF DIFFERENT DOSES OF CALCIDIOL ON 25(OH)D3 SERUM LEVELS AND ON MINERAL AND BONE METABOLIC MARKERS IN POSTMENOPAUSAL FEMALE SUBJECTS OVER 55 YEARS OF... | ||
Medical condition: Postmenopausal female subjects with inadequate levels or deficit of 25(OH)D3 | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: IT (Completed) | ||
Trial results: View results |
EudraCT Number: 2009-015247-16 | Sponsor Protocol Number: 162 | Start Date*: 2010-10-11 | |||||||||||
Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. | |||||||||||||
Full Title: A Randomized, Double-Blind, Active-Controlled, Multicenter Study of Patients with Primary Hypercholesterolemia and High Cardiovascular Risk Who Are Not Adequately Controlled with Atorvastatin 10 mg... | |||||||||||||
Medical condition: Primary Hypercholesterolemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) BE (Completed) FR (Completed) ES (Completed) FI (Completed) PT (Completed) DE (Completed) DK (Completed) SE (Completed) LT (Completed) EE (Completed) SI (Completed) SK (Completed) NL (Completed) CZ (Completed) BG (Completed) IT (Completed) HU (Completed) NO (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-000171-17 | Sponsor Protocol Number: SPD405-207 | Start Date*: 2012-10-02 | |||||||||||
Sponsor Name:Shire Pharmaceutical Development Ltd. | |||||||||||||
Full Title: A Three Part Open-Label Study to Assess the Pharmacokinetics of Lanthanum Carbonate, compare the Efficacy, Safety and Tolerability of 8 weeks treatment with Lanthanum Carbonate and Calcium Carbonat... | |||||||||||||
Medical condition: Treatment of Hyperphosphataemia. | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) DE (Completed) PL (Completed) Outside EU/EEA CZ (Completed) RO (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-005619-18 | Sponsor Protocol Number: Calcichew-4001 | Start Date*: 2015-05-05 | ||||||||||||||||
Sponsor Name:Takeda Development Centre Europe Ltd. | ||||||||||||||||||
Full Title: A Randomized, Open-Label, 2-Way Cross-over, Phase 4 Study to Evaluate Subject Preference and Acceptability of a New Formulation of Calcichew D3 in Adult Patients Eligible for Calcium and Vitamin D ... | ||||||||||||||||||
Medical condition: Prevention and treatment of vitamin D and calcium deficiency and adjunct to specific osteoporosis treatment of patients who are at risk of vitamin D and calcium deficiency | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (Completed) DE (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2012-005704-17 | Sponsor Protocol Number: AA1232 | Start Date*: 2013-03-27 | |||||||||||
Sponsor Name:Julie Gehl | |||||||||||||
Full Title: Calcium electroporation for the treatment of cutaneous metastases. | |||||||||||||
Medical condition: Patients suffering from advanced cancer with cutaneous metastases. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-005051-28 | Sponsor Protocol Number: 20140336 | Start Date*: 2016-08-22 | |||||||||||
Sponsor Name:Amgen Inc | |||||||||||||
Full Title: An Open-label, Single-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Etelcalcetide (AMG 416) in Paediatric Subjects Aged 2 to less than 18 Years with Sec... | |||||||||||||
Medical condition: Secondary Hyperparathyroidism (sHPT) Receiving Maintenance Haemodialysis | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) BE (Completed) LT (Completed) GB (Completed) PL (Completed) Outside EU/EEA | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
• EEA CTAs: Date study was authorised to proceed
• Outside EU/EEA: Date study was submitted in EudraCT
• Outside EU/EEA: Date study was submitted in EudraCT
